Stellar Biotechnologies Announces Appointment of New Director, David L. Hill, Ph. D.
Complete the form below to unlock access to ALL audio articles.
Stellar Biotechnologies, Inc. has announced that it has appointed David L. Hill, Ph.D. as a member of its board of directors.
Stellar’s new director, Dr. Hill, is a Board Certified High Complexity Laboratory Director, Board Certified Embryology Laboratory Director and member of the American Association of Bioanalysts.
He is Scientific Director of the ART Reproductive Center and is currently Assistant Clinical Professor, Dept. of Obstetrics and Gynecology at the David Geffen School of Medicine at UCLA and Research Assistant IV at Cedars-Sinai Medical Center.
After receiving his BS in Marine Biology at Cal Poly - San Luis Obispo, CA, Dr. Hill received his MS in Biological Sciences there then went on to a Ph.D. in Biological Sciences/Pathobiology at the University of Connecticut and post-doc Fellowship at The Dana Farber Cancer Institute (Appointment through the Department of Physiology and Biophysics, Harvard Medical School). He is listed on more than 100 peer-reviewed published papers.
Frank Oakes said, “Stellar is honored that Dr. Hill will bring his independence as well as an excellent scientific background and perspective, along with strong ties to the medical and regulatory arenas to our board. We very much look forward to working with him and gaining from his understanding.”
Dr. Hill said, “Stellar Biotechnologies is an extremely interesting and innovative company, and a leader in the development of important immune diagnostics and conjugate therapeutic vaccines. It will be interesting and exciting to participate in the development of these and other novel uses for KLH. I’m honored to join such a high caliber team.”
